- Company
- South Korea is looking forward to Xpovio's benefit
- by Aug 29, 2022 06:02am
- Xpovio, a treatment for multiple myeloma, succeeded in entering the benefit one after another overseas. Expectations are growing that the registration of overseas lists will have a positive effect on Korea, given that there has been no country to refer to drug prices. According to the pharmaceutical industry on the 25th, Canadian health au
- Company
- NPU condemns the unilateral ERP of multinational companies
- by Aug 29, 2022 06:02am
- The NPU condemned global pharmaceutical companies' unilateral ERP moves. The NPU, which gathered 16 domestic and foreign pharmaceutical bio companies, issued a statement on the 24th, signaling a strong response, saying, "Some member companies have recently shown unilateral voluntary retirement, wage negotiations that do not fit common sense,
- Company
- HK inno.N, Daewoong, & Jeil are competing to secure K-Cab
- by Kim, Jin-Gu Aug 29, 2022 06:02am
- Competition is expected to expand beyond P-CAB to PPI HK inno.N and Daewoong Pharmaceutical are competitively expanding the indication of P-CAB series gastroesophageal reflux disease treatment. On top of that, Jeil Pharmaceutical is planning to join the competition by operating two clinical trials at the same time to launch the third gast
- Company
- Zerbaxa on the verge of entering insurance benefits in 5 yrs
- by Eo, Yun-Ho Aug 26, 2022 05:35am
- The next-generation antibiotic Zerbaxa is finally registered as insurance benefits. It is the first time in five years that a domestic permit has been granted. According to related industries, MSD recently concluded a drug price negotiation with the NHIS for the antibiotic Zerbaxa. Due to the improvement of the system, it is possible to step
- Company
- First patient dosed with Yuhan’s degenerative disc drug
- by Aug 26, 2022 05:35am
- Yuhan Corp (President/CEO: Wook-Je Cho) announced on the 25th that the first patient was dosed with its new degenerative disc drug, “YH14618(SB-01, Remedisc).” The clinical trial was led by the US pharmaceutical company Spine BioPharma on 400 degenerative disc patients at 30 clinical sites in the US. The Phase III trial was conducte
- Company
- LG Chem Life Science achieves new quarterly sales record
- by Kim, Jin-Gu Aug 25, 2022 05:52am
- LG Chem’s Life Science company, which is in charge of the company’s pharmaceutical business, has broken its quarterly sales record in the second quarter of this year. Its flagship products - the Zemiglo series and growth hormone - had shown strong sales performance in Korea and abroad, rising nearly 20% in one year. According to the
- Company
- Celltrion Applies to Europe for IND to designate Yuflyma
- by Aug 24, 2022 05:55am
- Celltrion announced on the 23rd that it has applied to European regulators for IND to designate Humira biosimilar Yuflyma (CT-17) as an interchangeable similar. If it is designated as an interchangeable similar, it can be prescribed by replacing the original at a pharmacy without intervention by MD. Celltrion recently submitted IND to the
- Company
- Omega-3 prescription market doubles in 3 Years
- by Kim, Jin-Gu Aug 23, 2022 06:03am
- It is expected that generic companies will join and fierce competition is expected. The market for Omega-3 is rapidly expanding. The performance of outpatient prescriptions in the first half of the year has more than doubled in three years. The prescription performance of Omega-3 and Statins has increased significantly. It is predicted that c
- Company
- Abilify 1mg can be prescribed at tertiary hospitals
- by Eo, Yun-Ho Aug 22, 2022 05:53am
- A new 1mg strength formulation of ‘Abilify’ can now be prescribed at general hospitals According to industry sources, Korea Otsuka Pharmaceutical's antipsychotic ‘Abilify (aripiprazole)’ has passed the drug committees (DCs) of major hospitals in Korea, including the Seoul National University Hospital, Seoul Asan Medical Center, and Si
- Company
- Strong performance of overseas subsidiaries of companies
- by Kim, Jin-Gu Aug 22, 2022 05:52am
- Daewoong Pharmaceutical's Southeast Asian subsidiary doubled in a year. Major overseas subsidiaries of pharmaceutical bio companies showed strong sales in the first half of last year. Most of the local subsidiaries in China and Southeast Asia showed an increase in sales compared to the same period last year. Beijing Hanmi, Celltrion AP (Asia-
